Ben Franklin Technology Partners of Southeastern Pennsylvania
Ben Franklin Technology Partners of Southeastern Pennsylvania, established in 1982 and based in Philadelphia, is a prominent capital provider dedicated to the technology sectors within Pennsylvania. The organization specializes in both early-stage and established companies, with a focus on enhancing the region's innovation ecosystem across information technology, health, and physical sciences. Over its 30-year history, Ben Franklin has invested in more than 2,000 technology companies and has contributed over $170 million to drive regional growth. In addition to its investment activities, Ben Franklin fosters university and industry partnerships to facilitate the commercialization of scientific discoveries, while also supporting initiatives that bolster the local entrepreneurial community.
Corridor Pharmaceuticals
Series A in 2010
Corridor Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutic small molecule inhibitors of arginase. Its arginase is an enzyme that competes with endothelial nitric oxide synthase for the use of the common substrate l-arginine. The company's arginase also leads to the production of ornithine which increases polyamine, stimulating cell division, and contributing to hyperplasia and fibrosis. Corridor Pharmaceuticals, Inc. was formerly known as Arginetix, Inc. and changed its name to Corridor Pharmaceuticals, Inc. on June 17, 2010. The company was founded in 2007 and is based in Lutherville, Maryland.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.